1093071-69-2

Upstream product

• 773104-00-0 methyl 3-[(aminocarbonothioyl)amino]-4-methylbenzoate 
• 74-88-4 methyl iodide 
• 18595-18-1 3-amino-4-methyl benzoic acid methyl ester 

Downstream Products

• 773104-02-2 methyl 3-[4-[(2,4-difluorobenzyl)oxy]-2-(methylthio)-6-oxopyrimidin-1(6H)-yl]-4-methylbenzoate 
• 944154-49-8 3-[5-chloro-4-(2,4-difluoro-benzyloxy)-2-methylsulfanyl-6-oxo-6H-pyrimidin-1-yl]-4-methyl-benzoic acid 
• 773104-07-7 3-[5-chloro-4-(2,4-difluorobenzyloxy)-6-oxo-6H-pyrimidin-1-yl]-4-methylbenzoic acid 
• 1093071-71-6 C₂₀H₁₅ClF₂N₂O₅S 
• 1093071-70-5 C₂₀H₁₅ClF₂N₂O₆S 
• 1093071-59-0 3-[5-chloro-4-(2,4-difluorobenzyloxy)-6-oxo-6H-pyrimidin-1-yl]-N-[(R)-2-(2-methoxyethyl)-3-oxo-isoxazolidin-4-yl]-4-methylbenzamide 

Relevant academic research and scientific papers

KINASE INHIBITOR COMPOUNDS

Pyrimidinone derivatives have enhanced and unexpected drug properties as inhibitors of protein kinases and are useful in treating disorders related to abnormal protein kinase activities such as inflammatory diseases and certain types of cancer.

SUBSTITUTED PYRIMIDINONES

Disclosed are compounds Formula I and pharmaceutically acceptable salts thereof, wherein R1, R2, R4, and R5 are defined herein. These compounds are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical compositions containing the compounds, methods of preparing the compounds and methods of treatment using the compounds are also disclosed.